Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biofluid Biopsies

Dawne Shelton's Biography

Dawne Shelton, Senior Scientist, Bio-Rad Laboratories Digital Biology Center

Dawne Shelton received her BS in Biochemistry and Molecular Biology from the University of California, Santa Cruz. After 5 years working in biotech industry at Geron Corporation studying aging, telomerase, cancer, and stem cells, she pursued a PhD in Oncological Sciences from the University of Utah, Huntsman Cancer Institute investigating different aspects of the Wnt pathway in colon cancer. Dr. Shelton then went on to study the origins of the different subtypes of breast cancer by creating mouse models within the context of each mammary cell lineage. She moved to the University of Iowa and examined uterine cancer in a clinical cancer research lab. She is now a Senior Scientist at the Digital Biology Center focusing on developing applications and collaborations for ddPCR in the Cancer field.

Dawne Shelton Image

Droplet Digital PCR and the Liquid Biopsy

Monday, 27 October 2014 at 13:00

Add to Calendar ▼2014-10-27 13:00:002014-10-27 14:00:00Europe/LondonDroplet Digital PCR and the Liquid

Targeted therapies in many forms of cancer today have allowed unprecedented progress in the treatment of disease. Despite these advances, we currently lack simple, highly sensitive, yet inexpensive methods to follow the progression of disease with associated genomic markers. Some of the current major limitations are: 1) methods to detect, with confidence, mutational loads below 10%, 2) limited amounts of sample (pg-ng range) per biological specimen, 3) diagnostic turnaround time, and 4) cost. Droplet digital PCR is an inexpensive, rapid, and sensitive method for detecting a wide range of mutational loads in FFPE, cell free DNA and tissue. Absolute counting of target molecules enables precise measurement of input and accurate mutational loads without bias. We’ll summarize work covering the tracking of cell-free tumor DNA during  patient progression of disease and treatment monitoring, early detection in blood,  detection of copy number amplifications in blood, as well as the detection of KRAS mutations using a multiplex screening strategy.

Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonBiofluid